Celaid Therapeutics Secures 1.055 Billion JPY in Series B Financing's Initial Close Celaid Therapeutics recently completed the first close of its Series B financing, raising 1.055 billion JPY to advance its hematopoietic stem cell therapy, CLD-001.

Celaid Therapeutics Secures 1.055 Billion JPY in Series B Financing's Initial Close #Japan #Tokyo #Celaid_Therapeutics #CLD-001 #Hematopoietic_Stem_Cells

Celaid Therapeutics and AGC Join Forces to Advance iPSC Technology in Hematopoietic Cell Therapy Celaid Therapeutics and AGC have partnered to enhance iPSC-derived hematopoietic stem and progenitor cell technologies, tackling major challenges in cell therapy production.

Celaid Therapeutics and AGC Join Forces to Advance iPSC Technology in Hematopoietic Cell Therapy #Japan #Tokyo #AGC_Inc. #iPSC_Technology #Celaid_Therapeutics